SGLT2 Inhibitors: Unreal Primary Prevention? SGLT2 Inhibitors: Unreal Primary Prevention?
These diabetes drugs offer cardiovascular benefits, but only in diabetes patients who already have CV disease, the author argues.Medscape Diabetes & Endocrinology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Health | Heart | SGLT2 Inhibitors